{
    "code": "02022167",
    "url": "https:\/\/info.fda.gov.tw\/MLMS\/H0001D.aspx?Type=Lic&LicId=02022167",
    "time": "2020-02-25 12:51:28",
    "許可證字號": "衛署藥輸字第022167號",
    "註銷狀態": "已註銷",
    "註銷日期": "105\/06\/03",
    "註銷理由": "許可證已逾有效期",
    "製造許可登錄編號": "",
    "有效日期": "102\/05\/12",
    "發證日期": "87\/05\/12",
    "許可證種類": "製　劑",
    "舊證字號": "",
    "醫療器材級數": "",
    "通關簽審文件編號": "DHA00202216702",
    "中文品名": "敏克瘤注射液１公絲\/公撮",
    "英文品名": "VINCRISTINE-TEVA SOLUTION 1MG\/ML",
    "適應症": "可單獨使用或與其他化療藥品一起併用治療以下疾病：\r\n1. 急性淋巴球性白血病\r\n2. 惡性淋巴瘤，包括霍杰金與非霍杰金氏淋巴瘤\r\n3. 小細胞肺癌\r\n4. 伊汶氏肉瘤、胚胎型橫紋肌肉瘤、威爾姆氏腫瘤及神經母細胞瘤",
    "劑型": "270注射劑",
    "包裝": "盒裝 小瓶",
    "儲存溫度": "",
    "有效期間": "",
    "指示藥品審查基準": "",
    "標籤、仿單及包裝加註": "",
    "藥品類別": "05限由醫師使用",
    "管制藥品分類級別": "",
    "藥品分類": "",
    "監視期限": "",
    "主成分略述": "VINCRISTINE SULFATE",
    "限制項目": "02輸　入",
    "申請商名稱": "1011101100  海喬國際股份有限公司",
    "申請商地址": "台北市大同區重慶北路三段276號9樓",
    "主製造廠": [
        {
            "製造廠名稱": "FNL0029100  PHARMACHEMIE B.V.",
            "製造廠廠址": "SWENSWEG 5,2031 GA HAARLEM,THE NETHERLANDS",
            "製造廠公司地址": "SWENSWEG 5,P.O.BOX 552-2003 RN HAARLEM,THE NETHERLANDS",
            "製造廠國別": "NETHERLANDS",
            "製程": ""
        }
    ],
    "CCC號列": "30049071005 抗癌藥Anti-cancer preparations",
    "藥理治療分類": "",
    "ingredients": [
        {
            "成分類別": "主成分",
            "成分代碼": "1002000210",
            "成分名稱": "VINCRISTINE SULFATE",
            "含量描述": "1.00",
            "含量": "1.0000000000",
            "單位": "MG"
        }
    ],
    "仿單外盒": [
        {
            "title": "020221670003___20100729.pdf",
            "url": "https:\/\/www.fda.gov.tw\/MLMS\/ShowFile.aspx?LicId=02022167&Seq=003&Type=9"
        },
        {
            "title": "020221670007___20100729.pdf",
            "url": "https:\/\/www.fda.gov.tw\/MLMS\/ShowFile.aspx?LicId=02022167&Seq=007&Type=8"
        }
    ]
}